Pub Date : 2016-01-01DOI: 10.17925/EOH.2016.12.02.103
M. Risum, T. Barfod, K. Raaschou-Jensen
{"title":"Transient Elastography for the Detection of Hepatic Iron Overload in Patients with Myelodysplastic Syndrome","authors":"M. Risum, T. Barfod, K. Raaschou-Jensen","doi":"10.17925/EOH.2016.12.02.103","DOIUrl":"https://doi.org/10.17925/EOH.2016.12.02.103","url":null,"abstract":"","PeriodicalId":38554,"journal":{"name":"European Oncology and Haematology","volume":"39 1","pages":"103"},"PeriodicalIF":0.0,"publicationDate":"2016-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"83581831","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2016-01-01DOI: 10.17925/EOH.2016.12.01.19
J. Eriksen, M. Merlano
Despite technical advances the last decade, patients with HPV/p16 negative head and neck cancer (being smokers and having affected performance and co-morbidities), still have a poor outcome after treatment. Hyperfractionated radiotherapy with concurrent cisplatin might be a reasonable way to pursue for improving their outcome. This strategy requires that adequate supportive care is available. The term hyperfractionated radiotherapy (HFR) is used when radiotherapy is delivered in doses below 1.8-2.0 Gy per fraction. The rationale for doing so can be found in the differences in intrinsic radiosensitivity between tumours and late responding normal tissues. A small dose per fraction will tend to increase the therapeutic ratio between tumour and critical normal tissue and therefore allow a higher tumour dose to be given at the same level of normal tissue damage. This principle been extensively explored for squamous cell carcinomas arising in the head and neck region. The of HFR
{"title":"To hyperfractionate or not to hyperfractionate-Is it really a question?","authors":"J. Eriksen, M. Merlano","doi":"10.17925/EOH.2016.12.01.19","DOIUrl":"https://doi.org/10.17925/EOH.2016.12.01.19","url":null,"abstract":"Despite technical advances the last decade, patients with HPV/p16 negative head and neck cancer (being smokers and having affected performance and co-morbidities), still have a poor outcome after treatment. Hyperfractionated radiotherapy with concurrent cisplatin might be a reasonable way to pursue for improving their outcome. This strategy requires that adequate supportive care is available. The term hyperfractionated radiotherapy (HFR) is used when radiotherapy is delivered in doses below 1.8-2.0 Gy per fraction. The rationale for doing so can be found in the differences in intrinsic radiosensitivity between tumours and late responding normal tissues. A small dose per fraction will tend to increase the therapeutic ratio between tumour and critical normal tissue and therefore allow a higher tumour dose to be given at the same level of normal tissue damage. This principle been extensively explored for squamous cell carcinomas arising in the head and neck region. The of HFR","PeriodicalId":38554,"journal":{"name":"European Oncology and Haematology","volume":"76 1","pages":"19-20"},"PeriodicalIF":0.0,"publicationDate":"2016-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"83868036","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2016-01-01DOI: 10.17925/EOH.2016.12.02.81
J. Kiladjian, Y. Francis, J. Soret
{"title":"Optimising the Use of Ruxolitinib in Inadequately Controlled Polycythaemia Vera","authors":"J. Kiladjian, Y. Francis, J. Soret","doi":"10.17925/EOH.2016.12.02.81","DOIUrl":"https://doi.org/10.17925/EOH.2016.12.02.81","url":null,"abstract":"","PeriodicalId":38554,"journal":{"name":"European Oncology and Haematology","volume":"22 1","pages":"81"},"PeriodicalIF":0.0,"publicationDate":"2016-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"75912517","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2016-01-01DOI: 10.17925/EOH.2016.12.02.79
K. Gelmon
Karen Gelmon N ew treatments are needed urgently for advanced cancer of the breast, in which the most common subtype is hormone receptorpositive breast cancer. In the randomised, double-blind, multicentre phase III trial, Fulvestrant and AnastrozoLe COmpared in hormonal therapy Naïve advanced breast cancer (FALCON), a statistically significant 21% reduction in the risk of disease progression or death was reported in women with hormone receptor-positive advanced breast cancer who had been treated with fulvestrant compared with those who had received anastrozole. Women in this study had not received prior hormone therapy. Access to the treatment and the mechanisms for funding need to be facilitated in a timely fashion. Ongoing studies are awaited to help define the optimal sequence of therapy for women with hormone receptor-positive advanced breast cancer.
{"title":"Treatment Update for Women with Hormone Receptor-positive Advanced Breast Cancer","authors":"K. Gelmon","doi":"10.17925/EOH.2016.12.02.79","DOIUrl":"https://doi.org/10.17925/EOH.2016.12.02.79","url":null,"abstract":"Karen Gelmon N ew treatments are needed urgently for advanced cancer of the breast, in which the most common subtype is hormone receptorpositive breast cancer. In the randomised, double-blind, multicentre phase III trial, Fulvestrant and AnastrozoLe COmpared in hormonal therapy Naïve advanced breast cancer (FALCON), a statistically significant 21% reduction in the risk of disease progression or death was reported in women with hormone receptor-positive advanced breast cancer who had been treated with fulvestrant compared with those who had received anastrozole. Women in this study had not received prior hormone therapy. Access to the treatment and the mechanisms for funding need to be facilitated in a timely fashion. Ongoing studies are awaited to help define the optimal sequence of therapy for women with hormone receptor-positive advanced breast cancer.","PeriodicalId":38554,"journal":{"name":"European Oncology and Haematology","volume":"49 1","pages":"79"},"PeriodicalIF":0.0,"publicationDate":"2016-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"85324668","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2016-01-01DOI: 10.17925/EOH.2016.12.02.96
A. Spencer, S. Mithraprabhu
{"title":"Epigenetics in the biology and treatment of multiple myeloma","authors":"A. Spencer, S. Mithraprabhu","doi":"10.17925/EOH.2016.12.02.96","DOIUrl":"https://doi.org/10.17925/EOH.2016.12.02.96","url":null,"abstract":"","PeriodicalId":38554,"journal":{"name":"European Oncology and Haematology","volume":"42 1","pages":"96-102"},"PeriodicalIF":0.0,"publicationDate":"2016-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"78215602","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2016-01-01DOI: 10.17925/EOH.2016.12.02.87
P. Wuchter, K. Hübel
A utologous haematopoietic stem-cell transplantation (HSCT) is the standard treatment for a number of haematological malignancies. Achieving sufficient haematopoietic stem cell mobilisation is a prerequisite, but exactly how to define and achieve this goal remains a subject of debate. Key questions include which pharmacological agents to use, timing of treatments and mobilisation, and, in particular, target numbers of stem cells. Clinicians from Europe, North America and Asia compared their experiences and discussed these issues at a satellite workshop during the 3rd International Congress on Controversies in Stem Cell Transplantation and Cellular Therapies (COSTEM 2015). This review discusses the challenges of optimising leukapheresis in the context of these discussions. Although several studies suggest that the cell dose influences transplant outcomes in HSCT, other studies have not reached this conclusion. Recent data indicate that the graft composition also plays a role. More prospective study data are needed for a fuller understanding of engraftment outcomes using different mobilisation protocols.
{"title":"How to Find the Optimal Mobilisation Strategy – Impact, Challenges and Solutions","authors":"P. Wuchter, K. Hübel","doi":"10.17925/EOH.2016.12.02.87","DOIUrl":"https://doi.org/10.17925/EOH.2016.12.02.87","url":null,"abstract":"A utologous haematopoietic stem-cell transplantation (HSCT) is the standard treatment for a number of haematological malignancies. Achieving sufficient haematopoietic stem cell mobilisation is a prerequisite, but exactly how to define and achieve this goal remains a subject of debate. Key questions include which pharmacological agents to use, timing of treatments and mobilisation, and, in particular, target numbers of stem cells. Clinicians from Europe, North America and Asia compared their experiences and discussed these issues at a satellite workshop during the 3rd International Congress on Controversies in Stem Cell Transplantation and Cellular Therapies (COSTEM 2015). This review discusses the challenges of optimising leukapheresis in the context of these discussions. Although several studies suggest that the cell dose influences transplant outcomes in HSCT, other studies have not reached this conclusion. Recent data indicate that the graft composition also plays a role. More prospective study data are needed for a fuller understanding of engraftment outcomes using different mobilisation protocols.","PeriodicalId":38554,"journal":{"name":"European Oncology and Haematology","volume":"236 1","pages":"87"},"PeriodicalIF":0.0,"publicationDate":"2016-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"88562915","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2016-01-01DOI: 10.17925/EOH.2016.12.02.93
N. Kröger
C hronic graft-versus-host disease (GVHD) is a major cause of late morbidity and mortality post-allogeneic haematopoietic stemcell transplantation. Compared with acute GVHD, for which progress in preventative measures have been made, chronic GVHD describes a more diverse syndrome, and may adversely affect almost all organs in the body. A new prospective, multicentre, open-label, randomised phase III study (n=168) showed that the use of anti-human T-lymphocyte immune globulin (ATLG) in a myeloablative conditioning regimen for patients with acute leukaemia led to a significantly lower rate of chronic GVHD post-allogeneic transplantation compared with those receiving the same regimen without ATLG. Importantly, no increased rate of relapses in the patients who received ATLG was seen compared with those who did not. Thus, there was no apparent impairment in the graft-versus-leukaemia effect in ATLG-treated patients. The study was terminated at 2 years and more evidence about the long-term effect of ATLG on survival and GVHD relapses beyond this time-point are needed. Nonetheless, the findings represent a significant advance in the prevention of chronic GVHD.
{"title":"Prevention of Chronic Graft-versus-host Disease and the Unique Role of Anti-human T-lymphocyte Immune Globulin","authors":"N. Kröger","doi":"10.17925/EOH.2016.12.02.93","DOIUrl":"https://doi.org/10.17925/EOH.2016.12.02.93","url":null,"abstract":"C hronic graft-versus-host disease (GVHD) is a major cause of late morbidity and mortality post-allogeneic haematopoietic stemcell transplantation. Compared with acute GVHD, for which progress in preventative measures have been made, chronic GVHD describes a more diverse syndrome, and may adversely affect almost all organs in the body. A new prospective, multicentre, open-label, randomised phase III study (n=168) showed that the use of anti-human T-lymphocyte immune globulin (ATLG) in a myeloablative conditioning regimen for patients with acute leukaemia led to a significantly lower rate of chronic GVHD post-allogeneic transplantation compared with those receiving the same regimen without ATLG. Importantly, no increased rate of relapses in the patients who received ATLG was seen compared with those who did not. Thus, there was no apparent impairment in the graft-versus-leukaemia effect in ATLG-treated patients. The study was terminated at 2 years and more evidence about the long-term effect of ATLG on survival and GVHD relapses beyond this time-point are needed. Nonetheless, the findings represent a significant advance in the prevention of chronic GVHD.","PeriodicalId":38554,"journal":{"name":"European Oncology and Haematology","volume":"11 1","pages":"93"},"PeriodicalIF":0.0,"publicationDate":"2016-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"85803456","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2015-06-01DOI: 10.17925/EOH.2015.11.01.25
A. Carella, Clara Dellepiane, Davide Lovera, A. Ibatici, C. Ghiggi, A. Carella, G. Beltrami
Recently, the advent of imatinib has opened a new era in the treatment of chronic myeloid leukaemia (CML), leading to an impressive increase in overall survival rates. Today, many CML patients can expect to survive, if properly managed, likely similar to the general population. Recent progresses in CML stem cell biology have identified new leukogenetic pathways and therapeutic strategies that can be used to target the CML stem cell compartment. These studies have opened new perspectives in CML therapy and have highlighted major strategies for treating, and possibly eradicating, CML in the upcoming years.
{"title":"Chronic Myeloid Leukaemia - The Choice of Therapy and Future Perspectives","authors":"A. Carella, Clara Dellepiane, Davide Lovera, A. Ibatici, C. Ghiggi, A. Carella, G. Beltrami","doi":"10.17925/EOH.2015.11.01.25","DOIUrl":"https://doi.org/10.17925/EOH.2015.11.01.25","url":null,"abstract":"Recently, the advent of imatinib has opened a new era in the treatment of chronic myeloid leukaemia (CML), leading to an impressive increase in overall survival rates. Today, many CML patients can expect to survive, if properly managed, likely similar to the general population. Recent progresses in CML stem cell biology have identified new leukogenetic pathways and therapeutic strategies that can be used to target the CML stem cell compartment. These studies have opened new perspectives in CML therapy and have highlighted major strategies for treating, and possibly eradicating, CML in the upcoming years.","PeriodicalId":38554,"journal":{"name":"European Oncology and Haematology","volume":"14 1","pages":"25-29"},"PeriodicalIF":0.0,"publicationDate":"2015-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"81002027","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2015-06-01DOI: 10.17925/EOH.2015.11.01.15
M. Cappellini
Touch MEDical MEDia 15 Abstract Gaucher disease, which is caused by an inherited glucocerebrosidase deficiency, is the most prevalent lysosomal storage disease worldwide. Estimated prevalence of Gaucher disease is 1:50,000 in most countries and the disease has its highest incidence in the Ashkenazi Jewish population. Type 1 (non-neuropathic) Gaucher disease is by far the most common form. Gaucher disease type 1 should be considered in cases of unexplained splenomegaly with or without bleeding diathesis, skeletal manifestations or hepatomegaly. Diagnosis is made by demonstrating decreased glucocerebrosidase activity in peripheral blood leucocytes. Dried blood spots can be used for screening but conventional enzyme assay on heparinised blood is essential. Patients with Gaucher disease may have extensive organ involvement despite relatively minor overt symptomatology. Evidence suggests that Gaucher disease may remain undiagnosed for years, leading to severe complications that are preventable or reversible with enzyme replacement therapy. These complications include avascular necrosis, severe bleeding, chronic bone pain, pathological fractures, growth failure, liver pathology and life-threatening sepsis. Most patients with Gaucher disease are initially evaluated by a haematologist–oncologist. Improved education is needed to enable prompt detection of Gaucher disease. An increased risk of multiple myeloma and haematological and non-haematological malignancies has been reported in type 1 Gaucher disease. This review aims to offer familiarisation with a rare disorder in haematological practice, focusing on adult patient management.
{"title":"A Rare Condition in Haematological Practice – Gaucher Disease","authors":"M. Cappellini","doi":"10.17925/EOH.2015.11.01.15","DOIUrl":"https://doi.org/10.17925/EOH.2015.11.01.15","url":null,"abstract":"Touch MEDical MEDia 15 Abstract Gaucher disease, which is caused by an inherited glucocerebrosidase deficiency, is the most prevalent lysosomal storage disease worldwide. Estimated prevalence of Gaucher disease is 1:50,000 in most countries and the disease has its highest incidence in the Ashkenazi Jewish population. Type 1 (non-neuropathic) Gaucher disease is by far the most common form. Gaucher disease type 1 should be considered in cases of unexplained splenomegaly with or without bleeding diathesis, skeletal manifestations or hepatomegaly. Diagnosis is made by demonstrating decreased glucocerebrosidase activity in peripheral blood leucocytes. Dried blood spots can be used for screening but conventional enzyme assay on heparinised blood is essential. Patients with Gaucher disease may have extensive organ involvement despite relatively minor overt symptomatology. Evidence suggests that Gaucher disease may remain undiagnosed for years, leading to severe complications that are preventable or reversible with enzyme replacement therapy. These complications include avascular necrosis, severe bleeding, chronic bone pain, pathological fractures, growth failure, liver pathology and life-threatening sepsis. Most patients with Gaucher disease are initially evaluated by a haematologist–oncologist. Improved education is needed to enable prompt detection of Gaucher disease. An increased risk of multiple myeloma and haematological and non-haematological malignancies has been reported in type 1 Gaucher disease. This review aims to offer familiarisation with a rare disorder in haematological practice, focusing on adult patient management.","PeriodicalId":38554,"journal":{"name":"European Oncology and Haematology","volume":"110 1","pages":"15-20"},"PeriodicalIF":0.0,"publicationDate":"2015-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"76670961","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2015-01-01DOI: 10.17925/EOH.2015.11.01.39
E. Pennery
Disclosure: Emma Pennery is an employee of Breast Cancer Care. No funding was received in the publication of this article. Open Access: This article is published under the Creative Commons Attribution Noncommercial License, which permits any non-commercial use, distribution, adaptation and reproduction provided the original author(s) and source are given appropriate credit. Received: 6 February 2015 Accepted: 6 February 2015 Citation: European Oncology & Haematology, 2015;11(1):39–40 Correspondence: Emma Pennery, Breast Cancer Care, 5–13 Great Suffolk Street, London SE1 0NS, UK. E: info@breastcancercare.org.uk Breast Cancer Patients Continue to Struggle for Years After Diagnosis
爆料:Emma Pennery是乳腺癌护理中心的一名员工。这篇文章的出版没有收到任何资助。开放获取:本文在知识共享署名非商业性许可协议下发布，该协议允许任何非商业用途、分发、改编和复制，前提是原作者和来源必须得到适当的署名。收稿日期:2015年2月6日收稿日期:2015年2月6日Citation: European Oncology & Haematology, 2015;11(1): 39-40通信:Emma Pennery, Breast Cancer Care, 5-13 Great Suffolk Street, London SE1 0NS, UK。E: info@breastcancercare.org.uk乳腺癌患者在诊断后继续挣扎数年
{"title":"Breast Cancer Patients Continue to Struggle for Years After Diagnosis","authors":"E. Pennery","doi":"10.17925/EOH.2015.11.01.39","DOIUrl":"https://doi.org/10.17925/EOH.2015.11.01.39","url":null,"abstract":"Disclosure: Emma Pennery is an employee of Breast Cancer Care. No funding was received in the publication of this article. Open Access: This article is published under the Creative Commons Attribution Noncommercial License, which permits any non-commercial use, distribution, adaptation and reproduction provided the original author(s) and source are given appropriate credit. Received: 6 February 2015 Accepted: 6 February 2015 Citation: European Oncology & Haematology, 2015;11(1):39–40 Correspondence: Emma Pennery, Breast Cancer Care, 5–13 Great Suffolk Street, London SE1 0NS, UK. E: info@breastcancercare.org.uk Breast Cancer Patients Continue to Struggle for Years After Diagnosis","PeriodicalId":38554,"journal":{"name":"European Oncology and Haematology","volume":"120 1","pages":"39"},"PeriodicalIF":0.0,"publicationDate":"2015-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"81680230","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
京公网安备 11010802042870号
京ICP备2023020795号-1
扫码关注我们
求助内容：
应助结果提醒方式：